| Ident. | Authors (with country if any) | Title |
|---|
| 002838 (2013) |
Samantha Louise Smith [Royaume-Uni] ; Darren Plant [Royaume-Uni] ; Stephen Eyre [Royaume-Uni] ; Anne Barton [Royaume-Uni] | The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis |
| 002840 (2013) |
Mark C. Genovese [États-Unis] ; Roy M. Fleischmann [États-Unis] ; Maria Greenwald [États-Unis] ; Julie Satterwhite [États-Unis] ; Melissa Veenhuizen [États-Unis] ; Li Xie [États-Unis] ; Pierre-Yves Berclaz [États-Unis] ; Stephen Myers [États-Unis] ; Olivier Benichou [États-Unis] | Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors |
| 002851 (2013) |
Bernard Combe [France] ; Ronald Van Vollenhoven [Suède] | Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples |
| 002867 (2013) |
Tsutomu Takeuchi [Japon] ; Masayoshi Harigai [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Naoki Ishiguro [Japon] ; Kazuhiko Yamamoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Takao Koike [Japon] ; Minoru Kanazawa [Japon] ; Takuya Oba [Japon] ; Toru Yoshinari [Japon] ; Daniel Baker [États-Unis] | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks |
| 002868 (2013) |
Josef S. Smolen [Autriche] ; Daniel Aletaha [Autriche] | Forget personalised medicine and focus on abating disease activity |
| 002874 (2013) |
Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas] | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| 002875 (2013) |
Bente Glintborg [Danemark] ; Mikkel Stergaard [Danemark] ; Niels Steen Krogh [Danemark] ; Ulrik Tarp [Danemark] ; Natalia Manilo [Danemark] ; Anne Gitte Rasmussen Loft [Danemark] ; Annette Hansen [Danemark] ; Annette Schlemmer [Danemark] ; Victoria Fana [Danemark] ; Hanne M. Lindegaard [Danemark] ; Henrik Nordin [Danemark] ; Claus Rasmussen [Danemark] ; Leif Ejstrup [Danemark] ; Dorte Vendelbo Jensen [Danemark] ; Peter Mosborg Petersen [Danemark] ; Merete Lund Hetland [Danemark] | Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry |
| 002878 (2013) |
Monika M. Schoels [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho M. Murikama [Japon] ; Norihiro Nishimoto [Japon] ; Josef S. Smolen [Autriche] | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
| 002879 (2013) |
Paul Emery [Royaume-Uni] ; Anthony Sebba [États-Unis] ; Tom W J. Huizinga [Pays-Bas] | Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis |
| 002A08 (2013) |
I. Guseva ; N. Demidova ; N. Soroka [Russie] ; E. Panasyuk ; E. Luchikhina ; E. Fedorenko ; E. Alexandrova ; A. Novikov ; D. Trofimov [Russie] ; D. Karateev ; E. Nasonov | THU0164 Polymorphism of Cytotoxic T-Lymphocyte Antigen 4 +49A/G is Associated with Refractoriness to Non-Biological Dmards in Rheumatoid Arthritis Patients |
| 002A09 (2013) |
I. Ancuta ; C. Codreanu ; R. Ionescu ; M. Parvu [Roumanie] ; M. Bojinca | THU0163 Disease Flares Predict the Change to Second Line Therapy in Rheumatoid Arthritis: 9-Year Data from a Longitudinal Observational Study |
| 002A10 (2013) |
I. Ancuta ; C. Codreanu ; R. Ionescu ; M. Parvu [Roumanie] ; M. Bojinca | THU0162 Patterns of Clinical Response Predict Failure of TNF Inhibitor Treatment in Rheumatoid Arthritis: Data from a Longitudinal Observational Study in Romania |
| 002A15 (2013) |
J. Kremer [États-Unis] ; C. Zerbini [Brésil] ; E. B. Lee [Corée du Sud] ; D. Gruben [États-Unis] ; S. Krishnaswami [États-Unis] ; S. H. Zwillich [États-Unis] ; T. Koncz [États-Unis] ; J. Bradley [États-Unis] ; C. A. Mebus [États-Unis] | THU0143 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analyses of efficacy endpoints by subgroups in a pooled phase 2 and 3 rheumatoid arthritis study population |
| 002D01 (2013) |
J. Sieper [Allemagne] ; B. Porter-Brown [Royaume-Uni] ; L. Thompson [Royaume-Uni] ; O. Harari [Royaume-Uni] ; M. Dougados [France] | OP0166 Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial |
| 002E00 (2013) |
K. Michaud ; S. Pedro ; T. Simon [États-Unis] ; F. Wolfe | FRI0250 Are rheumatoid arthritis patients who receive abatacept comparable with those on other biologics? |
| 002E01 (2013) |
G. Jones [Australie] ; A. Sebba ; A. Anisfeld [États-Unis] ; J. Devenport [États-Unis] ; C. Bernasconi [Suisse] ; D. Smart [Royaume-Uni] ; D. Galindez [États-Unis] ; C. Mpofu [Suisse] ; J. Gomez-Reino [Espagne] | FRI0248 Long-term efficacy and safety of tocilizumab (TCZ) monotherapy in patients (PTS) with rheumatoid arthritis (RA) previously methotrexate (MTX) naive or mtx free for 6 months prior to study start |
| 002E04 (2013) |
J. Morel [France] ; M. O. Duzanski [France] ; A. Cantagrel [France] ; B. Combe [France] ; M. Dougados [France] ; R. M. Flipo ; J. E. Gottenberg [France] ; X. Mariette [France] ; O. Vittecoq ; A. Saraux ; T. Schaeverbeke ; T. Bardin [France] ; M. Soubrier ; P. Ravaud [France] ; J. Siblia [France] | FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra) |
| 002E05 (2013) |
A. Brodsky [États-Unis] ; E. Diri [États-Unis] ; I. Garcia-Delatorre [Mexique] ; D. F. Alvarez ; C. Bencan [États-Unis] ; J. Bukowski [États-Unis] ; C. Zang [États-Unis] | FRI0244 Clinical efficacy of 2 dosing regimens of tru-015, a b cell-depleting agent, in subjects with active seropositive rheumatoid arthritis compared with placebo on a stable background of methotrexate |
| 002E06 (2013) |
J. V. Tovar Beltrán ; M. A. Guzmán Beda ; I. Mateo Bernardo [Espagne] ; R. García-Vicu A [Espagne] ; M. Rodríguez-G Mez ; M. Belmonte-Serrano ; C. Marras ; E. Loza Cortina ; E. Pérez Pampin ; V. Vila ; A. Balsa [Espagne] | FRI0243 Act-life study: patterns of tocilizumab use, and dosing among patients with rheumatoid arthritis in the clinical practice. |
| 002E07 (2013) |
J. S. Smolen [Autriche] ; J. Wollenhaupt [Allemagne] ; P. Durez [Belgique] ; J. Gomez-Reino [Espagne] ; W. Grassi [Italie] ; M. Le Bars [France] ; C. Gaillez [France] ; C. Poncet [France] ; R. Westhovens [Belgique] | FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial |
| 002E61 (2013) |
C.-Y. Wu [États-Unis] ; X. Chen [États-Unis] ; H. Lu [États-Unis] ; E. Esfandiari ; F. Magrini ; A. Godwood [Royaume-Uni] ; P. Ryan ; C. Kane [États-Unis] ; L. Roskos [États-Unis] ; B. Wang [États-Unis] | FRI0182 Pharmacokinetics and immunogenicity of mavrilimumab administered subcutaneously in subjects with rheumatoid arthritis |
